| Type of support |
Approvals 2001-2023 (US$)(26 Dec 2018) |
Commitments 2001-2023 (US$)(26 Dec 2018) |
Disbursements 2000-2018 (US$)(26 Dec 2018) |
% Disbursed(26 Dec 2018) |
2002 |
2003 |
2004 |
2005 |
2006 |
2007 |
2008 |
2009 |
2010 |
2011 |
2012 |
2013 |
2014 |
2015 |
2016 |
2017 |
2018 |
2019 |
2020 |
2021 |
|---|
|
| Total |
$1,084,666,896 |
$1,241,187,039 |
$998,914,021 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cash Support (CASHSUPP) |
$169,668 |
$194,668 |
$169,668 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Civil Society Organisation support (CSO) |
$3,162,420 |
$3,162,420 |
$3,262,420 |
103% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cold Chain Equipment Optimisation Platform (CCEOP) |
$4,747,678 |
$20,875,664 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Health system strengthening (HSS 1) |
$76,493,935 |
$76,493,935 |
$76,493,935 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Health system strengthening (HSS 2) |
$61,405,575 |
$61,405,575 |
$61,405,575 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Health system strengthening (HSS 3) |
$63,165,802 |
$101,085,454 |
$47,815,802 |
76% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Health system strengthening (HSS 3 - PBF) |
|
|
|
N/A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HPV (NVS) |
$23,882,000 |
$34,541,500 |
$11,157,790 |
47% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HPV Demo (NVS) |
$147,439 |
$147,439 |
$147,439 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HPV MAC (NVS) |
$25,321,000 |
$58,617,500 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HPV MAC - Op costs (OPC) |
$1,812,209 |
$4,195,214 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Immunisation services support (ISS) |
$23,445,320 |
$23,445,320 |
$17,813,320 |
76% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Injection Safety Devices (NVS) |
$3,482,655 |
$5,261,655 |
$2,595,606 |
75% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Injection safety support (INS) |
$2,696,697 |
$2,696,697 |
$2,696,697 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IPV (NVS) |
$17,491,340 |
$17,491,340 |
$10,582,035 |
60% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Measles 1st and 2nd dose (NVS) |
$910,000 |
$1,823,500 |
$980,058 |
108% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Measles SIA (NVS) |
$8,458,031 |
$8,458,031 |
$8,458,031 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Measles SIA - Operational costs (OPC) |
$14,534,328 |
$14,534,328 |
$14,534,328 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Meningitis A - campaign (NVS) |
$43,030,647 |
$43,030,647 |
$44,310,479 |
103% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Meningitis A - operational costs (OPC) |
$33,779,677 |
$33,779,677 |
$33,779,677 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Penta (NVS) |
$240,229,387 |
$250,643,387 |
$241,594,757 |
101% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pneumo (NVS) |
$339,769,911 |
$368,307,411 |
$338,607,020 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Rotavirus (NVS) |
$85,798,471 |
$100,262,971 |
$71,776,844 |
84% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Vaccine Introduction Grant (VIG) |
$10,732,706 |
$10,732,706 |
$10,732,540 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Red line on table indicates duration of support based on commitments.
Commitments: Multi-year programme budgets endorsed in principle by the Gavi Board. These become financial commitments upon approval each year for the following calendar year.
Approvals: Total Approved for funding
Download data for commitments, approvals & disbursements in XLS format